Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?

about

Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?

Item

http://www.wikidata.org/entity/Q48263840

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ipragliflozin and sodium gluco ...... ll the prize we sought be won?

@en

Ipragliflozin and sodium gluco ...... ll the prize we sought be won?

@nl

type

Item

label

Ipragliflozin and sodium gluco ...... ll the prize we sought be won?

@en

Ipragliflozin and sodium gluco ...... ll the prize we sought be won?

@nl

prefLabel

Ipragliflozin and sodium gluco ...... ll the prize we sought be won?

@en

Ipragliflozin and sodium gluco ...... ll the prize we sought be won?

@nl

P1476

Ipragliflozin and sodium gluco ...... ll the prize we sought be won?

@en

P2093

Efstratios Maltezos

http://www.w3.org/2001/XMLSchema#string

Kalliopi Pafili

http://www.w3.org/2001/XMLSchema#string

Nikolaos Papanas

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions

Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update

Nonalcoholic fatty liver disease: a systematic review

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.

Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology.

Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.

The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.

P304

185-187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/14656566.2017.1413346

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29202593

http://www.w3.org/2001/XMLSchema#string